Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
36.46
+0.60 (1.67%)
At close: Aug 13, 2025, 4:00 PM
36.75
+0.29 (0.80%)
After-hours: Aug 13, 2025, 7:56 PM EDT
Royalty Pharma Revenue
Royalty Pharma had revenue of $578.67M in the quarter ending June 30, 2025, with 7.71% growth. This brings the company's revenue in the last twelve months to $2.31B, up 3.02% year-over-year. In the year 2024, Royalty Pharma had annual revenue of $2.26B, down -3.86%.
Revenue (ttm)
$2.31B
Revenue Growth
+3.02%
P/S Ratio
6.93
Revenue / Employee
$23,285,283
Employees
99
Market Cap
21.26B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RPRX News
- 11 hours ago - Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - GlobeNewsWire
- 4 days ago - Royalty Pharma: Keep Delivering, Buy Confirmed - Seeking Alpha
- 7 days ago - Royalty Pharma plc (RPRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Royalty Pharma Reports Second Quarter 2025 Results - GlobeNewsWire
- 26 days ago - Royalty Pharma Declares Third Quarter 2025 Dividend - GlobeNewsWire
- 27 days ago - Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors - GlobeNewsWire
- 4 weeks ago - Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 6 weeks ago - Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline - Seeking Alpha